Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC cut its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 7.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 220,834 shares of the biotechnology company’s stock after selling 18,065 shares during the period. Los Angeles Capital Management LLC’s holdings in Heron Therapeutics were worth $439,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Capital Investment Counsel Inc increased its holdings in Heron Therapeutics by 27.2% in the 2nd quarter. Capital Investment Counsel Inc now owns 14,625 shares of the biotechnology company’s stock worth $51,000 after buying an additional 3,125 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Heron Therapeutics by 15.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,922 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 3,991 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Heron Therapeutics by 16.0% during the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 6,328 shares during the last quarter. nVerses Capital LLC acquired a new position in Heron Therapeutics during the second quarter valued at $27,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Heron Therapeutics by 21.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 7,927 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Heron Therapeutics Stock Down 4.0 %

NASDAQ:HRTX opened at $1.19 on Friday. Heron Therapeutics, Inc. has a 52 week low of $0.81 and a 52 week high of $3.93. The stock’s 50-day moving average price is $1.82 and its 200-day moving average price is $2.51. The stock has a market capitalization of $180.99 million, a PE ratio of -6.61 and a beta of 1.81.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same period in the previous year, the business posted ($0.17) earnings per share. Sell-side analysts expect that Heron Therapeutics, Inc. will post -0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HRTX. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC lowered their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.